135: Can LVRS Postpone Lung Transplantation in Emphysema Patients?

Asian (2%) recipients. Diagnosis leading to transplantation was cystic fibrosis in 37 (61%), interstitial lung disease in 9 (15%), pulmonary hypertension in 5 (8%), cystic lung disease in 4 (7%), non-post-lung transplant bronchiolitis obliterans (BO) in 4 (7%) and post-lung transplant BO in 2 (3%). There were no intra-op deaths. Survival at 1, 3 and 5 years after transplantation was 83%, 68% and 60%, respectively (Figure). Grade 3 primary graft dysfunction (PGD) was seen in 27% of the cohort. Among 17 patients who died, 6 (32%) died because of severe PGD and complications associated with it. The second leading cause of death was BO, responsible for 5 deaths (26%). Other causes of death were adenovirus pneumonia in 2 (14%), fungal infections in 2 (14%), RSV pneumonia in 1 (7%) and humoral rejection in 1 (7%). Number of acute rejection episodes per 100-patient days was: 0.5. Seven patients developed PTLD (11%). BOS-free survival was 62% at 2 years post-transplant. Conclusions: Our findings indicate that children with end-stage lung disease have encouraging survival results after lung transplantation.